Skip Navigation

Adalvo announces successful DCP Submission for Empagliflozin Film-Coated Tablets

07 September 2023

We are pleased to announce our successful DCP submission for Empagliflozin 25mg film-coated tablets, which was developed in collaboration with one of our strategic partners.

Our product has been developed based on the reference brand Jardiance 25mg film-coated tablets, which is indicated in the treatment of type 2 diabetes mellitus.

The brand sold approximately $14bn globally in 2022, having a significant growth potential with Global 3Y CAGR at +26%, according to IQVIA.

Adalvo is one of the few companies having an extensive offering of both small molecule and peptide treatment possibilities for type 2 diabetes, as depicted below.

Partner up now! 

At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.

Get in touch with your preferred Business Partner today! - Head of Global BD&L - LATAM (exc. Brazil) – Brazil - LATAM (exc. Brazil) & South Europe – Central & Eastern Europe, Russia & CIS North Europe, APAC, MENA & Israel – Europe – UK/Ireland, North America & South Africa

Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.